Triphenyl monomers suitable for microstructured optical films
US-9221743-B2 · Dec 29, 2015 · US
Functionalized stilbene derivatives as improved vascular targeting agents
USRE45720E · US · E1
| Field | Value |
|---|---|
| Publication number | US-RE45720-E |
| Application number | US-201414180209-A |
| Country | US |
| Kind code | E1 |
| Filing date | Feb 13, 2014 |
| Priority date | Oct 26, 2001 |
| Publication date | Oct 6, 2015 |
| Grant date | Oct 6, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of the formula: wherein: R 1 , R 4 and R 5 is independently H, OH, lower alkoxy, NH 2 , NO 2 , N 3 , NH—R 6 , halogen, a phosphate ester salt moiety of the general formula (—O—P(O)(O − M + ) 2 or (—OP(O)(OR 9 )(O − M + ); or —OPO 3 R 7 R 8 ; R 2 is H, OH, lower alkoxy, NH 2 , NO 2 , NH—R 6 , or phosphate ester salt moiety of the ge…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent USRE45720E cover?
- Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent …
- Who is the assignee on this patent?
- Oxigene Inc, Univ Baylor
- What technology area does this patent fall under?
- Primary CPC classification C07C43/23. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (E1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).